Cardiology Xagena
Results from the phase III STARS J-V ( Studying Thrombosis After Replacement Surgery ) study have shown Edoxaban ( Lixiana ), a direct factor Xa inhibitor, to be superior to Enoxaparin ( Lovenox ) in ...
Edoxaban ( Savaysa ) is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of Edoxaban as compared with Warfarin ( Coumadin ) in patients with atri ...
Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...
At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...
Edoxaban ( Lixiana ), an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation. P-glyco ...
At the end of two previous trials, an excess of stroke and bleeding was observed in patients with atrial fibrillation randomized to a new oral anticoagulant ( NOAC ) who transitioned to a vitamin K an ...
The aim of a study was to evaluate the population pharmacokinetics ( PK ) and exposure-response relationship of Edoxaban ( Lixiana, Savaysa ) in patients with non-valvular atrial fibrillation ( AF ). ...
New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vit ...
In the ENGAGE AF-TIMI 48 trial, the higher-dose Edoxaban ( HDE; Lixiana, Savaysa ) regimen had a similar incidence of ischaemic stroke compared with Warfarin ( Coumadin ), whereas a higher incidence w ...
A study has compared efficacy and safety among novel oral anticoagulants ( NOACs ), which have not been directly compared in randomized control trials to date. Investigators performed network meta- ...
Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic events is clinically perce ...
Results from the global phase 3b ENSURE-AF ( EdoxabaN vs warfarin in subjectS UndeRgoing cardiovErsion of AtrialFibrillation ) study of 2,199 patients with non-valvular atrial fibrillation ( NVAF ) un ...
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting. The results ...
